Literature DB >> 16449977

Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells.

L Patrawala1, T Calhoun, R Schneider-Broussard, H Li, B Bhatia, S Tang, J G Reilly, D Chandra, J Zhou, K Claypool, L Coghlan, D G Tang.   

Abstract

CD44 is a multifunctional protein involved in cell adhesion and signaling. The role of CD44 in prostate cancer (PCa) development and progression is controversial with studies showing both tumor-promoting and tumor-inhibiting effects. Most of these studies have used bulk-cultured PCa cells or PCa tissues to carry out correlative or overexpression experiments. The key experiment using prospectively purified cells has not been carried out. Here we use FACS to obtain homogeneous CD44(+) and CD44(-) tumor cell populations from multiple PCa cell cultures as well as four xenograft tumors to compare their in vitro and in vivo tumor-associated properties. Our results reveal that the CD44(+) PCa cells are more proliferative, clonogenic, tumorigenic, and metastatic than the isogenic CD44(-) PCa cells. Subsequent molecular studies demonstrate that the CD44(+) PCa cells possess certain intrinsic properties of progenitor cells. First, BrdU pulse-chase experiments reveal that CD44(+) cells colocalize with a population of intermediate label-retaining cells. Second, CD44(+) PCa cells express higher mRNA levels of several 'stemness' genes including Oct-3/4, Bmi, beta-catenin, and SMO. Third, CD44(+) PCa cells can generate CD44(-) cells in vitro and in vivo. Fourth, CD44(+) PCa cells, which are AR(-), can differentiate into AR(+) tumor cells. Finally, a very small percentage of CD44(+) PCa cells appear to undergo asymmetric cell division in clonal analyses. Altogether, our results suggest that the CD44(+) PCa cell population is enriched in tumorigenic and metastatic progenitor cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16449977     DOI: 10.1038/sj.onc.1209327

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  398 in total

1.  Cancer-associated fibroblasts derived from EGFR-TKI-resistant tumors reverse EGFR pathway inhibition by EGFR-TKIs.

Authors:  Sheldon R Mink; Surabhi Vashistha; Wenxuan Zhang; Amanda Hodge; David B Agus; Anjali Jain
Journal:  Mol Cancer Res       Date:  2010-06-08       Impact factor: 5.852

Review 2.  Chemoattractant receptors as pharmacological targets for elimination of glioma stem-like cells.

Authors:  Xiao-hong Yao; Ying Liu; Keqiang Chen; Wanghua Gong; Ming-yong Liu; Xiu-wu Bian; Ji Ming Wang
Journal:  Int Immunopharmacol       Date:  2011-09-17       Impact factor: 4.932

Review 3.  Prostate cancer stem cell biology.

Authors:  C Yu; Z Yao; Y Jiang; E T Keller
Journal:  Minerva Urol Nefrol       Date:  2012-03       Impact factor: 3.720

4.  Selective inhibitory effect of HPMA copolymer-cyclopamine conjugate on prostate cancer stem cells.

Authors:  Yan Zhou; Jiyuan Yang; Jindřich Kopeček
Journal:  Biomaterials       Date:  2011-12-03       Impact factor: 12.479

Review 5.  Concise review: Cancer stem cells and minimal residual disease.

Authors:  Gabriel Ghiaur; Jonathan Gerber; Richard J Jones
Journal:  Stem Cells       Date:  2012-01       Impact factor: 6.277

6.  CD44 is a biomarker associated with human prostate cancer radiation sensitivity.

Authors:  WeiWei Xiao; Peter H Graham; Carl A Power; Jingli Hao; John H Kearsley; Yong Li
Journal:  Clin Exp Metastasis       Date:  2011-09-28       Impact factor: 5.150

Review 7.  The androgen receptor and stem cell pathways in prostate and bladder cancers (review).

Authors:  Katarzyna Marcinkiewicz; Kymora B Scotland; Stephen A Boorjian; Emeli M Nilsson; Jenny Liao Persson; Per Anders Abrahamsson; Cinzia Allegrucci; Ieuan A Hughes; Lorraine J Gudas; Nigel P Mongan
Journal:  Int J Oncol       Date:  2011-09-28       Impact factor: 5.650

8.  MAOA-mediated reprogramming of stromal fibroblasts promotes prostate tumorigenesis and cancer stemness.

Authors:  Jingjing Li; Tianjie Pu; Lijuan Yin; Qinlong Li; Chun-Peng Liao; Boyang Jason Wu
Journal:  Oncogene       Date:  2020-02-17       Impact factor: 9.867

9.  HPMA copolymer-based combination therapy toxic to both prostate cancer stem/progenitor cells and differentiated cells induces durable anti-tumor effects.

Authors:  Yan Zhou; Jiyuan Yang; Johng S Rhim; Jindřich Kopeček
Journal:  J Control Release       Date:  2013-09-14       Impact factor: 9.776

10.  Combination therapy of prostate cancer with HPMA copolymer conjugates containing PI3K/mTOR inhibitor and docetaxel.

Authors:  Yan Zhou; Jiyuan Yang; Rui Zhang; Jindřich Kopeček
Journal:  Eur J Pharm Biopharm       Date:  2014-12-03       Impact factor: 5.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.